HexemBio is building the first blood stem cell rejuvenation therapy, using a Synthetic Human Yolk Sac platform that returns a patient's own hematopoietic stem cells to an embryonic-like state and re-infuses them via standard IV: a wedge into regenerative medicine that sidesteps the instability risks of gene editing and transcription-factor reprogramming. The lead program targets bone marrow transplant in blood cancer patients, an indication with FDA Orphan Drug Designation.
Validation is scientific and regulatory rather than commercial: technology published in Nature, zero failures across 400 mice, FDA Orphan Designation and a completed Pre-IND / Type A meeting, and non-dilutive support including a $6.9M NIH Phase II contract and a $1M NYC retention grant (per Meeting Notes rec5NHw9og7rGZ0VG, 2026-05-14). Since StoryHouse's entry the company has marked up through stacked SAFEs at escalating caps ($15M then $20M, $25M, $35M, $40M) and is preparing a $45-50M Series A. SH committed $100K via StoryHouse Fund I at a $15M cap in a $4M round, alongside Alumni Ventures, SOSV, Draper VC, and E2MC Ventures.
HexemBio sits in the cellular-reprogramming corner of the longevity market, a small but fast-compounding segment (roughly 20% CAGR) riding advances in epigenetic reprogramming and heavy venture inflows. The near-term reachable market is narrower: the lead indication is a specific bone marrow transplant (hematopoietic stem cell) use case in blood cancer, which the orphan designation and NIH/DOD interest help define.
| Company | Approach | Notes |
|---|---|---|
| HexemBio | Synthetic Human Yolk Sac: places a patient's own HSCs in an embryonic-like niche, re-infused via IV | Nature-published; FDA Orphan Designation; licensing 15+ patents |
| NewLimit | Epigenetic / transcription-factor reprogramming of aged cells (immune, endothelial, hepatocytes) | Raised $130M (2025) then $435M; Coinbase's Brian Armstrong backed Web |
| Retro Biosciences | Yamanaka-factor reprogramming; replacing old blood stem cells with young ones | ~$1B raised; Sam Altman-backed Web |
| Ensoma / HemoGenyx / Magenta | HSC gene therapy and bone marrow transplant conditioning / engineering | Listed as nearest tracked competitors Web |
Moat: HexemBio's differentiation is its niche-recreation mechanism (a synthetic yolk sac that avoids editing the genome), Nature-validated data, an FDA orphan-designated lead indication, and a growing licensed patent portfolio (15+), which together separate it from the transcription-factor and Yamanaka-factor approaches of much larger, better-capitalized rivals.
Traction is scientific and regulatory: publications, orphan designation, a completed Pre-IND/Type A meeting, and meaningful non-dilutive funding, alongside an expanding pipeline (HS01 bone marrow transplant, HS01.1 radiation countermeasure, EXS02 cosmetic wound healing, and a women's-health/menopause program). There is no commercial revenue and no human clinical data yet.
The most likely exit is acquisition by a large pharma or cell/gene-therapy player in hematology and regenerative medicine (the space occupied by tracked peers Magenta, Ensoma, and HemoGenyx), with an IPO possible if the platform generates human data. Longevity-specific M&A remains modest but real: Daewoong's move on Turn Bio brought an established pharma into age-reversal assets Web, though HexemBio is far earlier than that comparable and any exit is many clinical milestones away.
Scientific co-founders include Samira Kiani (US Presidential Award recipient) and Mo Ebrahimkhani; advisory board includes Robert Langer (Moderna founder) and George Church (per Company record and Meeting Notes rec5NHw9og7rGZ0VG).
K&M call with Gabriel. Company progress and funding: completed seed round extension ($35M cap moving to $40M); Draper Ventures reinvested; multiple existing investors participated; current runway ~28 months.
Non-dilutive pipeline: NYC retention grant of $1M for the lab they are keeping there (possibly requires staying in NYC ~7 years); NIH Phase II $6.9M contract; DOD bone marrow transplant program (pending submission); BARDA discussions ongoing (9-12 month timeline expected).
Regulatory and clinical: HS01 (bone marrow transplant improvement) received FDA orphan designation, completed the FDA Type A meeting and responded to concerns, with toxicology studies nearing completion and an IND filing target of Q3 2026 (aggressive); hired a 5-person consulting team for IND prep. HS01.1 (radiation countermeasure) follows the same regulatory path, aligned to a government MCM program and tested on the same leukemia patient population.
Pipeline expansion: EXS02 (cosmetic wound healing) moving to TRL4 with subdermal injection delivery, no animal testing required, celebrity partnerships (an Olympic medalist plus an undisclosed second), synthetic-skin testing, target launch Q3 2026 (delays expected). A women's-health/menopause indication is in development with George Church involvement, to be disclosed at Series A.
Partnerships and advisors: George Church advisory role (licensing 15+ patents); three potential CVCs in discussion for EXS02 (one major cosmetic company plus one international partner, territory-based exclusivity); an upcoming press release co-mentioning Church, Colossal, and Hexem (clarified to be a co-mention, not a partnership).
Series A prep: target $45-50M, potentially by June 2026 and by September 2026 at the latest; current valuation ~$11M with max dilution to $15M this round. Keith flagged three key inflection points (tox completion, IND filing, IND approval); Gabriel seemed less cognizant of their individual importance to fundraising. Next steps: Gabriel to send updated cap table and latest SAFE terms and continue Series A discussions with investment updates.
Source: Meeting Notes rec5NHw9og7rGZ0VGKH Q&A with Gabriel Levesque Tremblay. On Draper: Tim Draper's fund (Draper VC) invested $1M. On the raise: ~$6.03M raised on simple YC post-money SAFEs at different valuation caps. On oversubscription: open to $1-3M of additional room on the post-money SAFE, with $1.2M of $3M already committed.
Source: Meeting Notes rec1qjxNyz0K3RVuzKeith's notes: little to no DD yet; Keith knows the CEO and has doubts about his ability to be a CEO; do we have any follow-up planned with them?
Source: Meeting Notes recNnfnlzzFvdiQwR